---
title: "3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to Analysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292353106.md"
description: "Analysts highlight high-risk, high-reward stocks in cell therapy, advanced materials, and nuclear power, specifically Cabaletta Bio (CABA), Onterris (ONT), and Nano Nuclear Energy (NNE). For CABA, Jefferies maintains a Buy rating with a $14 target following positive EULAR data on rese-cel. Wall Street consensus is Strong Buy, with an average price target of $15.75 implying 430.3% upside potential."
datetime: "2026-07-10T19:48:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292353106.md)
  - [en](https://longbridge.com/en/news/292353106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292353106.md)
---

# 3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to Analysts

High‑risk, high-reward stocks can swing sharply, but they can also deliver big gains when their strategy plays out. Analysts are bullish about a few small names that belong to fast‑moving sectors such as cell therapy, advanced materials, and nuclear power, such as Cabaletta Bio (CABA), Onterris (ONT), and Nano Nuclear Energy (NNE).

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

## **1\. Cabaletta Bio (CABA)**

Cabaletta Bio is developing cell therapies for autoimmune diseases. This space has drawn strong interest as new data shows engineered T‑cells may help treat conditions like lupus and myasthenia gravis. The company's pipeline could unlock major value if upcoming clinical readouts go well.

Last month, Jefferies analyst Roger Song kept a Buy and $14 target on Cabaletta Bio after new EULAR data. The analyst said rese‑cel shows deep, long‑lasting B‑cell depletion with strong responses across autoimmune diseases.

Turning to Wall Street, CABA stock has a Strong Buy consensus rating based on six Buys and one Hold assigned in the last three months. The average Cabaletta Bio stock price target of $15.75 implies upside potential of 430.3%.

### Related Stocks

- [ONT.US](https://longbridge.com/en/quote/ONT.US.md)
- [NNE.US](https://longbridge.com/en/quote/NNE.US.md)
- [CABA.US](https://longbridge.com/en/quote/CABA.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Only 2 of These 5 Nuclear Stocks Sell Fuel Today. Here's What the Market Pays for the Other 3.](https://longbridge.com/en/news/295308623.md)
- [Onterris Q2 revenue misses estimates, cuts 2026 outlook](https://longbridge.com/en/news/295007315.md)
- [Got $1,000? Here are my favorite nuclear stocks to invest in right now.](https://longbridge.com/en/news/295306036.md)
- [ALA: Off-the-shelf CAR-iNKT therapy to begin first patient dosing, targeting broad oncology and autoimmune indications](https://longbridge.com/en/news/295614845.md)
- [ALA: Off-the-shelf CAR-iNKT therapy nears first patient dosing, targeting broad oncology and autoimmune markets](https://longbridge.com/en/news/295620311.md)